A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Capecitabine (XELODA)

Capecitabine interferes with DNA synthesis to slow cancer cell or viral replication.

First FDA approval1998-04-30
Generic availableYes · 11 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$74,309 in CY2024 Part D spend249 claims · 80 beneficiaries · 329 plans surveyed

Lowest NADAC
$0.396/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.430
Across all dosage forms in distribution.
Highest NADAC
$0.510
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Capecitabine used for?

Capecitabine interferes with DNA synthesis to slow cancer cell or viral replication.

Is there a generic for Capecitabine?

Yes. 22 ANDAs filed at FDA, 11 generic manufacturers currently shipping.

How much does my plan pay for Capecitabine?

Across 329 Part D plans, Capecitabine averages $0.430/unit (NADAC). Lowest available: $0.396/unit. Highest in distribution: $0.510/unit.

Is Capecitabine on the FDA shortage list?

No. Capecitabine is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Nucleoside Metabolic Inhibitor6 alternatives in D1
01
(Daunorubicin and Cytarabine) Liposome
Brand: VYXEOS
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Azacitidine
Brand: ONUREG
Lowest NADAC
13Generic mfrs
$138.5MCY24 Part D spend
Compare →
03
Azacitidine For
Brand: AZACITIDINE
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Cedazuridine and Decitabine
Brand: INQOVI
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Clofarabine
Nucleoside Metabolic Inhibitor
Lowest NADAC
8Generic mfrs
CY24 Part D spend
Compare →
06
Cytarabine
Nucleoside Metabolic Inhibitor
Lowest NADAC
7Generic mfrs
$557CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.